A Phase I, Randomized, Double-Blind, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557, A Humanized Monoclonal Antibody With an Extended Half-Life Against Respiratory Syncytial Virus (RSV), in Healthy Adults.

Trial Profile

A Phase I, Randomized, Double-Blind, Single-Dose, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI-557, A Humanized Monoclonal Antibody With an Extended Half-Life Against Respiratory Syncytial Virus (RSV), in Healthy Adults.

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Sep 2013

At a glance

  • Drugs Motavizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Most Recent Events

    • 30 Sep 2013 Results published in Antimicrobial Agents and Chemotherapy.
    • 15 Mar 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 May 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top